Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma

Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: دکتر حسن نمازی , رویا صالحی قره ورن

کلمات کلیدی: β-Cyclodextrin, Fluorescent carbon quantum dot, Dual-responsive nanogels, Controlled co-drug release, D-galactose, Targeted human liver cancer treatment

نشریه: 11061 , 2022 , 167 , 2022

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله دکتر حسن نمازی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات ریز فناوری دارویی
کد مقاله 78451
عنوان فارسی مقاله Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma
عنوان لاتین مقاله Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma
ناشر 3
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

In the current research work for the first time, we designed and fabricated a new double-responsive (pH and temperature) and photoluminescent nanogels capped with D-galactose (D-Gal) moieties (CQDs/β-CD/NIPAM@AA-Gal) in three steps and then evaluated its potential as a targeted drug carrier. The used common characterization techniques approved the success in fabrication of the CQDs/β-CD/NIPAM@AA-Gal nanogels. CQDs/β-CD/NIPAM@AA-Gal nanogels demonstrated homogeneous size distribution with an average hydrodynamic diameter of about 657 nm. About 47.8% and 72% of loading capacity respectively were observed respectively for methotrexate (MTX) and doxorubicin (DOX) anticancer drugs (MTX@DOX@CQDs/β-CD/NIPAM@AA-Gal). The controlled drug release ability of the MTX@DOX@CQDs/β-CD/NIPAM@AA-Gal was verified through a comparison of the drug release profiles at the simulated tumor and physiological conditions. In vitro cytotoxicity, 4′,6-diamidino-2-phenylindole (DAPI) staining, and cell cycle assays displayed the good biocompatibility of CQDs/β-CD/NIPAM@AA-Gal. Furthermore, fluorescent imaging approved its bioimaging potential. Overall summation of the achieved results proposes that the CQDs/β-CD/NIPAM@AA-Gal can be generally tested as a medical nanovehicle with a wide range of applicability potential for cancer cells monitoring and co-drug delivery.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
دکتر حسن نمازیدوم
رویا صالحی قره ورنسوم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
10 P 2022 Poores_Salehi(European Polymer ).pdf1401/01/1711628106دانلود